ClinicalTrials.gg
Active, not recruitingNCT07220759RENEW 2Updated Nov 16, 2026

Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

A Phase 3 interventional study of Cagrilintide and Placebo (matched to Cagrilintide) in Overweight, Obesity and Type 2 Diabetes, sponsored by Novo Nordisk A/S. Active, not recruiting at 67 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing cagrilintide in Obesity — 9 open to participants now, 15 under way, 9 of them phase 3. cagrilintide · Obesity.

Planned enrollment
12th of 36
330 · median 154
Started
2025
with 5 others
Phase 3
15 of 36
4 open now
Primary completion
2027-05
later than 3 of 14 live
Registered
25th of 36
by date
Lead sponsor
36 of 36
Novo Nordisk A/S

Among the 36 studies testing cagrilintide in Obesity, this one is the 12th largest by planned enrollment, is one of 6 that started in 2025, is one of 15 in phase 3, reaches primary completion later than 3 of the 14 other live ones, and was the 25th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

9 of the 36 studies testing cagrilintide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About cagrilintide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing cagrilintide in Obesity, or all of them as a file.
02

Study summary

This study will look at how much cagrilintide helps people with overweight or obesity and type 2 diabetes lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participant will either get cagrilintide or placebo. Which treatment participant get is decided by chance. Participants are two times more likely to get cagrilintide than placebo. Like all medicines, the study medicine may have side effects. For each participant, the study will last for about 1 year and 6 months.

03

Conditions studied

  • Overweight
  • Obesity
  • Type 2 Diabetes

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

This study's planned enrollment of 330 is above the median of 67 across 9,016 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
  • Female or male (sex at birth).
  • Age 18 years or above at the time of signing the informed consent.
  • History of at least one self-reported unsuccessful dietary effort to lose body weight.(a*)
  • (BMI) >= 27.0 kilogram per square meter (kg/m\^2).
  • Diagnosed with type 2 diabetes >= 180 days before screening.(a*)
  • Treatment with either lifestyle intervention(a*), or:

    • Stable treatment (same drug(s), dose and dosing frequency) for at least 90 days before screening with 1-3 marketed oral antidiabetic drugs (metformin, α-glucosidase inhibitors (AGI), glinides, sodium-glucose cotransporter 2 inhibitor (SGLT2i), thiazolidinediones, Dipeptidyl peptidase-4 inhibitor (DPP-4i) or sulphonylureas (SU) as a single agent or in combination according to local practice.(a*)
    • For up to 30% of participants the following concomitant medication is allowed:

      • Treatment for any indication with a stable dose of glucagon-like peptide-1 (GLP-1) containing medication, stable for at least 1 year before screening (a*) and/or
      • Treatment with basal insulin minimum (0.25 units per kilogram per day (U/kg/day) or 20 units per day [U/day]) stable for at least 90 days before screening.(a*)

Key Exclusion Criteria:

  • Treatment, or intention to initiate treatment, with any medication prescribed for the indication of weight management within 180 days before screening.(a*)
  • Treatment with glucagon-like peptide-1 (GLP-1) receptor agonist (RA) or GLP-1 containing medication within 180 days before screening, apart from those randomized according to inclusion criteria 7bi.(a*)
  • Previous dosing of marketed or non-marketed amylin-based compounds.(a*) (a*) - As declared by the participant, reported in the medical records or at the investigator's discretion.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
330 participants (estimated)

Study arms

  • Experimental
    Cagrilintide

    Participants will receive cagrilintide subcutaneously once weekly for 64 weeks.

    Drug: Cagrilintide

  • Placebo comparator
    Placebo

    Participants will receive placebo matched to cagrilintide subcutaneously once weekly for 64 weeks.

    Drug: Placebo (matched to Cagrilintide)

Interventions

  • Cagrilintide will be administered subcutaneously with a pen-injector as an adjunt to lifestyle intervention counselling.

  • DrugPlacebo (matched to Cagrilintide)

    Placebo matched to cagrilintide will be administered subcutaneously with a pen-injector as an adjunt to lifestyle intervention counselling.

07

What researchers measure

Primary outcomes

  1. Relative change in body weight

    Measured as percentage (%) of body weight.

    Time frame: From baseline (week 0) to end of treatment (week 64)

Secondary outcomes

  1. Number of participants with achievement of >= 10% body weight reduction (yes/no)

    Measured as count of participants.

    Time frame: From baseline (week 0) to end of treatment (week 64)

  2. Number of participants with achievement of >= 15% body weight reduction (yes/no)

    Measured as count of participants.

    Time frame: From baseline (week 0) to end of treatment (week 64)

  3. Change in waist circumference

    Measured as centimeter (cm).

    Time frame: From baseline (week 0) to end of treatment (week 64)

  4. Ratio to baseline in lipids: triglycerides

    Measured as ratio.

    Time frame: From baseline (week 0) to end of treatment (week 64)

  5. Ratio to baseline in high sensitivity C-reactive protein (hsCRP)

    Measured as ratio.

    Time frame: From baseline (week 0) to end of treatment (week 64)

  6. Change in glycated haemoglobin (HbA1c)

    Measured as percentage of HbA1c.

    Time frame: From baseline (week 0) to end of treatment (week 64)

  7. Change in impact of weight on quality of life-lite clinical trials version (IWQOL-Lite-CT) physical function score

    Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. The physical function score ranges from 0-100.

    Time frame: From baseline (week 0) to end of treatment (week 64)

  8. Change in systolic blood pressure (SBP)

    Measured as millimeter of mercury (mmHg).

    Time frame: From baseline (week 0) to end of treatment (week 64)

  9. Change in body weight

    Measured as kilogram (kg).

    Time frame: From baseline (week 0) to end of treatment (week 64)

  10. Number of participants with achievement of >= 5% body weight reduction (yes/no)

    Measured as count of participants.

    Time frame: From baseline (week 0) to end of treatment (week 64)

  11. Change in SF-36v2® health survey acute (SF-36v2® acute) physical component summary score

    Measured as score on a scale. SF-36v2 Acute measures Health-Related Quality of Life (HRQoL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. The physical component summary score ranges from 6.1 to 79.7.

    Time frame: From baseline (week 0) to end of treatment (week 64)

  12. Change in SF-36v2® mental component summary score

    Measured as score on a scale. SF-36v2 Acute measures Health-Related Quality of Life (HRQoL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. The mental component summary score ranges from -3.8 to 78.7.

    Time frame: From baseline (week 0) to end of treatment (week 64)

  13. Change in IWQOL-Lite-CT total score

    Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. The total score ranges from 0-100.

    Time frame: From baseline (week 0) to end of treatment (week 64)

  14. Number of participants with achievement of at least 14.6-point increase (yes/no) in IWQOL-Lite-CT physical function score

    Measured as count of participants. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. The physical function score ranges from 0-100.

    Time frame: From baseline (week 0) to end of treatment (week 64)

  15. Change in diastolic blood pressure (DBP)

    Measured as mmHg.

    Time frame: From baseline (week 0) to end of treatment (week 64)

  16. Ratio to baseline in lipids: total cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to end of treatment (week 64)

  17. Ratio to baseline in lipids: high-density lipoprotein (HDL) cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to end of treatment (week 64)

  18. Ratio to baseline in lipids: low-density lipoprotein (LDL) cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to end of treatment (week 64)

  19. Ratio to baseline in lipids: very low-density lipoprotein (VLDL) cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to end of treatment (week 64)

  20. Ratio to baseline in lipids: non-HDL cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to end of treatment (week 64)

  21. Ratio to baseline in lipids: free fatty acids

    Measured as ratio.

    Time frame: From baseline (week 0) to end of treatment (week 64)

  22. Change in fasting plasma glucose (FPG) in millimole per liter (mmol/L)

    Measured as mmol/L.

    Time frame: From baseline (week 0) to end of treatment (week 64)

  23. Change in FPG in milligram per deciliter (mg/dL)

    Measured as mg/dL.

    Time frame: From baseline (week 0) to end of treatment (week 64)

  24. Ratio to baseline in fasting serum insulin

    Measured as ratio.

    Time frame: From baseline (week 0) to end of treatment (week 64)

  25. Number of treatment emergent adverse events

    Measured as count of events.

    Time frame: From baseline (week 0) to end of study (week 71)

  26. Number of treatment emergent serious adverse events (TESAEs)

    Measured as count of events.

    Time frame: From baseline (week 0) to end of study (week 71)

  27. Number of clinically significant hypoglycaemic episodes (level 2):<3.0 mmol/L [54 mg/dL], confirmed by blood glucose meter

    Measured as count of events.

    Time frame: From baseline (week 0) to end of study (week 71)

  28. Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold

    Measured as count of events.

    Time frame: From baseline (week 0) to end of study (week 71)

08

Study locations

67 sites
09

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for May 2027, 18 months after the start.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 18 months is below that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2025
First posted
Oct 24, 2025
StartActual
Nov 5, 2025
Primary completionEst.
May 12, 2027
CompletionEst.
Jun 30, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
2 updates, last Nov 16, 2026
Show all 2 updates
  1. Nov 16, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 7, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07220759
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Oct 24, 2025
Start date
Nov 5, 2025
Primary completion
May 12, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Clinical Transparency' (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cagrilintide

Start the discussion